1RUE

RHINOVIRUS 14 SITE DIRECTED MUTANT N1219A COMPLEXED WITH ANTIVIRAL COMPOUND WIN 52035


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.9 Å

wwPDB Validation 3D Report Full Report


This is version 1.2 of the entry. See complete history

Literature

Structural studies on human rhinovirus 14 drug-resistant compensation mutants.

Hadfield, A.T.Oliveira, M.A.Kim, K.H.Minor, I.Kremer, M.J.Heinz, B.A.Shepard, D.Pevear, D.C.Rueckert, R.R.Rossmann, M.G.

(1995) J.Mol.Biol. 253: 61-73

  • DOI: 10.1006/jmbi.1995.0536
  • Primary Citation of Related Structures:  

  • PubMed Abstract: 
  • Structures have been determined of three human rhinovirus 14 (HRV14) compensation mutants that have resistance to the antiviral capsid binding compounds WIN 52035 and WIN 52084. In addition, the structure of HRV14 is reported, with a site-directed mu ...

    Structures have been determined of three human rhinovirus 14 (HRV14) compensation mutants that have resistance to the antiviral capsid binding compounds WIN 52035 and WIN 52084. In addition, the structure of HRV14 is reported, with a site-directed mutation at residue 1219 in VP1. A spontaneous mutation occurs at the same site in one of the compensation mutants. Some of the mutations are on the viral surface in the canyon and some lie within the hydrophobic binding pocket in VP1 below the ICAM footprint. Those mutant virus strains with mutations on the surface bind better to cells than does wild-type virus. The antiviral compounds bind to the mutant viruses in a manner similar to their binding to wild-type virus. The receptor and WIN compound binding sites overlap, causing competition between receptor attachment and antiviral compound binding. The compensation mutants probably function by shifting the equilibrium in favor of receptor binding. The mutations in the canyon increase the affinity of the virus for the receptor, while the mutations in the pocket probably decrease the affinity of the WIN compounds for the virus by reducing favorable hydrophobic contacts and constricting the pore through which the antiviral compounds are thought to enter the pocket. This is in contrast to the resistant exclusion mutants that block compounds from binding by increasing the bulk of residues within the hydrophobic pocket in VP1.


    Related Citations: 
    • Three Dimensional Structures of Drug-Resistant Mutants of Human Rhinovirus 14
      Badger, J.,Krishnaswamy, S.,Kremer, M.J.,Oliveira, M.A.,Rossmann, M.G.,Heinz, B.A.,Rueckert, R.R.,Dutko, F.J.,Mckinlay, M.A.
      (1989) J.Mol.Biol. 207: 163
    • Win 52035-2 Inhibits Both Attachment and Eclipse of Human Rhinovirus 14
      Shepard, D.A.,Heinz, B.A.,Rueckert, R.R.
      (1993) J.Virol. 67: 2245
    • Analysis of the Structure of a Common Cold Virus, Human Rhinovirus 14, Refined at a Resolution of 3.0 Angstroms
      Arnold, E.,Rossmann, M.G.
      (1990) J.Mol.Biol. 211: 763
    • Structural Analysis of Antiviral Agents that Interact with the Capsid of Human Rhinoviruses
      Badger, J.,Minor, I.,Oliveira, M.A.,Smith, T.J.,Rossmann, M.G.
      (1989) Proteins 6: 1
    • Structure of a Human Common Cold Virus and Functional Relationship to Other Picornaviruses
      Rossmann, M.G.,Arnold, E.,Erickson, J.W.,Frankenberger, E.A.,Griffith, J.P.,Hecht, H.-J.,Johnson, J.E.,Kamer, G.,Luo, M.,Mosser, A.G.,Rueckert, R.R.,Sherry, B.,Vriend, G.
      (1985) Nature 317: 145
    • Virion Orientation in Cubic Crystals of the Human Common Cold Virus Hrv14
      Arnold, E.,Erickson, J.W.,Fout, G.S.,Frankenberger, E.A.,Hecht, H.-J.,Luo, M.,Rossmann, M.G.,Rueckert, R.R.
      (1984) J.Mol.Biol. 177: 417
    • The Site of Attachment in Human Rhinovirus 14 for Antiviral Agents that Inhibit Uncoating
      Smith, T.J.,Kremer, M.J.,Luo, M.,Vriend, G.,Arnold, E.,Kamer, G.,Rossmann, M.G.,Mckinlay, M.A.,Diana, G.D.,Otto, M.J.
      (1986) Science 233: 1286
    • Structural Analysis of a Series of Antiviral Agents Complexed with Human Rhinovirus 14
      Badger, J.,Minor, I.,Kremer, M.J.,Oliveira, M.A.,Smith, T.J.,Griffith, J.P.,Guerin, D.M.A.,Krishnaswamy, S.,Luo, M.,Rossmann, M.G.,Mckinlay, M.A.,Diana, G.D.,Dutko, F.J.,Fancher, M.,Rueckert, R.R.,Heinz, B.A.
      (1988) Proc.Natl.Acad.Sci.USA 85: 3304
    • The Structure Determination of a Common Cold Virus, Human Rhinovirus 14
      Arnold, E.,Vriend, G.,Luo, M.,Griffith, J.P.,Kamer, G.,Erickson, J.W.,Johnson, J.E.,Rossmann, M.G.
      (1987) Acta Crystallogr.,Sect.A 43: 346
    • Genetics and Molecular Basis for Resistance of Human Rhinovirus 14 to an Antiviral Drug
      Heinz, B.A.,Rueckert, R.R.,Shepard, D.A.,Dutko, F.J.,Mckinlay, M.A.,Fancher, M.,Rossmann, M.G.,Badger, J.,Smith, T.J.
      (1989) J.Virol. 63: 2476
    • The Use of Molecular Replacement Phases for the Refinement of the Human Rhinovirus 14 Structure
      Arnold, E.,Rossmann, M.G.
      (1988) Acta Crystallogr.,Sect.A 44: 270


    Organizational Affiliation

    Department of Biological Sciences, Purdue University, West Lafayette, IN 47907-1392, USA.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
RHINOVIRUS 14
1
289Human rhinovirus 14Mutation(s): 1 
Find proteins for P03303 (Human rhinovirus 14)
Go to UniProtKB:  P03303
Entity ID: 2
MoleculeChainsSequence LengthOrganismDetails
RHINOVIRUS 14
2
262Human rhinovirus 14Mutation(s): 0 
Find proteins for P03303 (Human rhinovirus 14)
Go to UniProtKB:  P03303
Entity ID: 3
MoleculeChainsSequence LengthOrganismDetails
RHINOVIRUS 14
3
236Human rhinovirus 14Mutation(s): 0 
Find proteins for P03303 (Human rhinovirus 14)
Go to UniProtKB:  P03303
Entity ID: 4
MoleculeChainsSequence LengthOrganismDetails
RHINOVIRUS 14
4
68Human rhinovirus 14Mutation(s): 0 
Find proteins for P03303 (Human rhinovirus 14)
Go to UniProtKB:  P03303
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
W35
Query on W35

Download SDF File 
Download CCD File 
1
5-(5-(4-(4,5-DIHYDRO-2-OXAZOLY)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE
WIN VI; WIN 52035
C18 H22 N2 O3
IWZDYGHUSXWPPM-UHFFFAOYSA-N
 Ligand Interaction
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.9 Å
  • Space Group: P 21 3
Unit Cell:
Length (Å)Angle (°)
a = 445.100α = 90.00
b = 445.100β = 90.00
c = 445.100γ = 90.00
Software Package:
Software NamePurpose
PURDUEdata reduction

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

Revision History 

  • Version 1.0: 1995-11-14
    Type: Initial release
  • Version 1.1: 2008-03-24
    Type: Version format compliance
  • Version 1.2: 2011-07-13
    Type: Version format compliance